PerkinElmer
check quantity

Total CHK2 AlphaLISA SureFire Ultra Detection Kit, HV

The AlphaLISA® SureFire® Ultra™ Total CHK2 assay is a sandwich immunoassay for quantitative detection of total CHK2 in cellular lysates using Alpha Technology.

For research use only; not for diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).

Part Number
Unit Size
List Price
Your Price
Quantity
ALSU-TCHK2-A500
500 Assay Points
1868.00 USD
 
more
ALSU-TCHK2-A10K
10,000 Assay Points
11400.00 USD
 
more
ALSU-TCHK2-A50K
50,000 Assay Points
36700.00 USD
 
more
ALSU-TCHK2-A-HV
100 Assay Points
553.00 USD
 
more
Buy Now

Please enter valid quantity

Please log in to add favorites.

NULL OR EMPTY CART

Overview

Checkpoint kinase 2 (CHK2) is a serine-threonine kinase and an integral member of the signaling cascade that controls the G1 cell cycle checkpoint. CHK2 is activated in response to DNA double-strand breaks and phosphorylates several modulators of cell cycle control including tumor suppressor proteins and prevents unchecked cell division. Mutations in CHK2 are linked to a wide range of cancers, such as breast, lung, prostate, kidney, and thyroid. 

The AlphaLISA SureFire Ultra Total CHK2 assay is a sandwich immunoassay for the quantitative detection of Total CHK2 in cellular lysates, using Alpha Technology.

Formats:

  • The HV (high volume) kit contains reagents to run 100 wells in 96-well format, using a 60 μL reaction volume.
  • The 500-point kit contains enough reagents to run 500 wells in 384-well format, using a 20 μL reaction volume.
  • The 10,000-point kit contains enough reagents to run 10,000 wells in 384-well format, using a 20 μL reaction volume.
  • The 50,000-point kit contains enough reagents to run 50,000 wells in 384-well format, using a 20 μL reaction volume.

AlphaLISA SureFire Ultra kits are compatible with:

  • Cell and tissue lysates
  • Antibody modulators
  • Biotherapeutic antibodies

Alpha SureFire kits can be used for:

  • Cellular kinase assays
  • Receptor activation studies
  • Screening

Specifications

Assay Target CHK2
Assay Technology Alpha
Automation Compatible Yes
Detection Method Alpha
Experimental Type In vitro
Product Brand Name AlphaLISA SureFire Ultra
Shipping Condition Blue Ice
Unit Size 100 Assay Points
Resources, Events & More
  • All

Application Brief

Eight Limitations of ELISA and How to Overcome Them Using Alternative Technologies

The introduction of enzyme-linked immunosorbent assays (ELISAs) in the early 1970’s offered researchers a non-radiometric immunoassay platform without compromising sensitivity. Over the last 50 years scientists have made huge strides in disease research and drug discovery and a demand for greater assay throughput and sensitivity has evolved. In response, more robust immunoassays have been developed to address some of the limitations of the standard, colorimetric ELISA.

Find out about the most common limitations of traditional ELISAs and how different ELISA alternative technologies address these limitations.

PDF 1 MB

Brochure

Alpha Technology Solutions

Product brochure for the Alpha Technology, a versatile, no wash, homogeneous assay technology that's suitable for a broad range of applications.

PDF 4 MB
Drug Discovery Screening Solutions Brochure

Find out about our range of integrated solutions for drug discovery screening in this e-brochure.

Our screening solutions for high-throughput screening, phenotypic screening and data analysis help to streamline drug discovery workflows in labs across the globe. Our portfolio includes automated liquid handling, assays and reagents, imaging and detection systems, and informatics.

Working independently or together, with our solutions you can achieve consistent and accurate results. By accelerating the identification and characterization of effective and safe drug candidates, the PerkinElmer portfolio enables you to optimize efficiency in your lab and deliver more actionable, real-world results.

Download the brochure to learn more about how we can partner with you so that you can discover smarter, more effective, data-driven breakthroughs in the critical screening stages of drug discovery and development.

PDF 4 MB